GSK announces tender offer to acquire Nuvalent

AI SummaryClose X

GSK plc has commenced a tender offer to acquire all outstanding shares of Nuvalent, Inc. for $124.00 per share in cash, aiming to acquire Nuvalent as a wholly-owned subsidiary through a subsequent merger. The offer, which is not subject to a financing condition, is contingent on a minimum tender of a majority of Nuvalent's Class A shares and regulatory approvals, with the tender offer expiring on July 14, 2026, unless extended. Nuvalent's Board of Directors has recommended that its stockholders accept the offer.

Disclaimer*

Companies

GSK (GSK)
UK 100

Latest directors dealings